Liposomal daunorubicin (trade name DaunoXome) is a chemotherapy drug that is FDA approved to treat AIDS related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.
See also
External links
- Women&Cancer Magazine Liposomal daunorubicin
- Johns Hopkins AIDS Service - New from the Food and Drug Administration (FDA)
- "DaunoXome", Drugs.com explanation
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |